Xtant Medical Reports First Quarter 2024 Revenue Growth of 55% and Raises Full Year 2024 Revenue Guidance
Xtant Medical (NYSE American:XTNT) reported a 55% revenue increase for Q1 2024, reaching $27.9 million compared to $17.9 million in Q1 2023. The growth was driven by acquisitions and increased sales of Coflex and CoFix products.
Gross margin improved to 62.1%, up from 58.7% in the prior year. However, the company recorded a net loss of $4.3 million, higher than the $2.1 million loss in Q1 2023. Adjusted EBITDA turned positive at $0.1 million from a loss of $0.3 million in the previous year.
Xtant launched two new amniotic membrane allografts and amended credit agreements for more working capital. The company raised its 2024 revenue guidance to $116 million - $120 million, indicating a 27%-31% growth compared to 2023.
- Revenue increased by 55% to $27.9 million in Q1 2024.
- Gross margin improved to 62.1%, up 340 basis points from the prior year.
- Adjusted EBITDA turned positive at $0.1 million compared to a loss of $0.3 million in Q1 2023.
- Revenue guidance for full year 2024 raised to $116 million - $120 million, a 27%-31% growth.
- Launched two new amniotic membrane allografts, SimpliGraft™ and SimpliMax™.
- Amended credit agreements to provide additional working capital.
- Net loss increased to $4.3 million from $2.1 million in Q1 2023.
- Operating expenses rose to $20.8 million, up from $12.1 million in the previous year.
- Cash and cash equivalents decreased to $4.5 million from $5.7 million as of December 31, 2023.
Insights
Xtant Medical's financial performance for Q1 2024 shows notable improvement, especially with
This quarter's performance is mixed with both strong revenue growth and significant expenses. The guidance raise to
Xtant Medical's growth trajectory has benefited from strategic acquisitions and increased sales efforts. The inclusion of Surgalign Holdings' assets has clearly provided a substantial revenue boost. Yet, short-term supply chain challenges remain a hurdle, particularly for their biologics and spinal hardware product lines. The company's ability to navigate these issues while maintaining growth will be critical for sustained performance.
Notably, Xtant's investment in vertical integration of their supply chain could mitigate these issues over time, reducing dependency on external suppliers and improving margins further. Retail investors should monitor how effectively Xtant leverages these acquisitions and manages costs moving forward.
Expects Revenue for Full Year 2024 of
BELGRADE, MT / ACCESSWIRE / May 15, 2024 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the first quarter ended March 31, 2024.
First Quarter 2024 Financial Highlights
- Revenue of
$27.9 million , up55% , compared to the prior year quarter - Gross margin of
62.1% , up 340 basis points, compared to the prior year quarter - Net loss of
$4.4 million compared to$2.1 million in the year ago quarter - Positive Adjusted EBITDA; Adjusted EBITDA of
$0.1 million compared to an Adjusted EBITDA loss of$0.3 million in the prior year quarter
Recent Business Highlights
- Launched two amniotic membrane allografts, SimpliGraft™ and SimpliMax™
- Amended its Term Credit and Revolving Credit Agreements to provide additional working capital
Sean Browne, President and CEO of Xtant Medical, stated, "In the first quarter of 2024, we delivered strong revenue growth of
First Quarter 2024 Financial Results
Total revenue for the three months ended March 31, 2024 was
Gross margin for the first quarter of 2024 was
Operating expenses for the first quarter of 2024 totaled
Net loss for the first quarter of 2024 was
Non-GAAP Adjusted EBITDA for the first quarter of 2024 was
As of March 31, 2024, the Company had
2024 Financial Guidance
Xtant Medical raises its expectation for full year 2024 revenue to
Conference Call
Xtant Medical will host a webcast and conference call to discuss first quarter 2024 financial results at 4:30 pm ET on Wednesday, May 15, 2024.
To access the webcast, visit https://www.webcaster4.com/Webcast/Page/3039/50597.
To access the conference call, dial 877-545-0523 within the U.S. or 973-528-0016 outside the U.S. A replay of the call will be available on the Investor section of the Company's website at www.xtantmedical.com.
About Xtant Medical Holdings, Inc.
Xtant Medical's mission of honoring the gift of donation so that our patients can live as full and complete a life as possible, is the driving force behind our company. Xtant Medical Holdings, Inc. (www.xtantmedical.com) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.
The symbols ™ and ® denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in the United States, and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.
Non-GAAP Financial Measures
To supplement the Company's consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses certain non-GAAP financial measures in this release, including Adjusted EBITDA. Reconciliations of the non-GAAP financial measures used in this release to the most comparable GAAP measures for the respective periods can be found in tables later in this release. The Company's management believes that the presentation of these measures provides useful information to investors. These measures may assist investors in evaluating the Company's operations, period over period. Management uses the non-GAAP measures in this release internally for evaluation of the performance of the business, including the allocation of resources. Investors should consider non-GAAP financial measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as "intends," ‘‘expects,'' ‘‘anticipates,'' ‘‘plans,'' ‘‘believes,'' ‘‘estimates,'' "continue," "future," ‘‘will,'' "potential," "going forward," "guidance," similar expressions or the negative thereof, and the use of future dates. Forward-looking statements in this release include the Company's financial guidance for 2024, plans related to its product launches and supply chain improvements. The Company cautions that its forward-looking statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the Company's future operating results and financial performance; its ability to increase or maintain revenue; risks associated with its acquisitions and the integration of those businesses; anticipated shortages of stem cells which will adversely affect future revenues; possible future impairment charges to long-lived assets and goodwill and write-downs of excess inventory; the ability to remain competitive; the ability to innovate, develop and introduce new products and the success of those products; the ability to engage and retain new and existing independent distributors and agents and qualified personnel and the Company's dependence on key independent agents for a significant portion of its revenue; the effect of COVID-19, labor and hospital staffing shortages on the Company's business, operating results and financial condition, especially when they affect key markets; the Company's ability to implement successfully its future growth initiatives and risks associated therewith; the effect of inflation, increased interest rates and other recessionary factors and supply chain disruptions; the effect of product sales mix changes on the Company's financial results; government and third-party coverage and reimbursement for Company products; the ability to obtain and maintain regulatory approvals and comply with government regulations; the effect of product liability claims and other litigation to which the Company may be subject; the effect of product recalls and defects; the ability to obtain and protect Company intellectual property and proprietary rights and operate without infringing the rights of others; risks associated with the Company's clinical trials; international risks; the ability to service Company debt, comply with its debt covenants and access additional indebtedness; the ability to obtain additional financing on favorable terms or at all; and other factors. Additional risk factors are contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission (SEC) on April 1, 2024 and subsequent SEC filings by the Company, including without limitation its most recent Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2024 anticipated to be filed with the SEC. Investors are encouraged to read the Company's filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by this cautionary statement.
Investor Relations Contact:
Brett Maas
Managing Partner, Hayden IR
brett@haydenir.com
(646) 536-7331
XTANT MEDICAL HOLDINGS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except number of shares and par value)
| March 31, 2024 | December 31, 2023 | |||||||
| (Unaudited) | ||||||||
ASSETS | ||||||||
Current Assets: | ||||||||
Cash and cash equivalents | $ | 4,547 | $ | 5,715 | ||||
Restricted cash | 77 | 208 | ||||||
Trade accounts receivable, net of allowance for credit losses and doubtful accounts of | 21,484 | 20,731 | ||||||
Inventories | 38,724 | 36,885 | ||||||
Prepaid and other current assets | 1,709 | 1,330 | ||||||
Total current assets | 66,541 | 64,869 | ||||||
Property and equipment, net | 8,867 | 8,692 | ||||||
Right-of -use asset, net | 1,437 | 1,523 | ||||||
Goodwill | 7,302 | 7,302 | ||||||
Intangible assets, net | 9,652 | 10,085 | ||||||
Other assets | 132 | 141 | ||||||
Total Assets | $ | 93,931 | $ | 92,612 | ||||
LIABILITIES & STOCKHOLDERS' EQUITY | ||||||||
Current Liabilities: | ||||||||
Accounts payable | $ | 7,378 | $ | 7,054 | ||||
Accrued liabilities | 9,875 | 10,419 | ||||||
Current portion of lease liability | 853 | 830 | ||||||
Current portion of finance lease obligations | 66 | 65 | ||||||
Line of credit | 10,270 | 4,622 | ||||||
Total current liabilities | 28,442 | 22,990 | ||||||
Long-term Liabilities: | ||||||||
Lease liability, less current portion | 644 | 759 | ||||||
Finance lease obligation, less current portion | 99 | 116 | ||||||
Long-term debt, plus premium and less issuance cost | 16,826 | 17,167 | ||||||
Other liabilities | 240 | 231 | ||||||
Total Liabilities | 46,251 | 41,263 | ||||||
Stockholders' Equity | ||||||||
Preferred stock, | - | - | ||||||
Common stock, | - | - | ||||||
Additional paid-in capital | 295,223 | 294,330 | ||||||
Accumulated other comprehensive (loss) income | (133 | ) | 29 | |||||
Accumulated deficit | (247,410 | ) | (243,010 | ) | ||||
Total Stockholders' Equity | 47,680 | 51,349 | ||||||
Total Liabilities & Stockholders' Equity | $ | 93,931 | $ | 92,612 | ||||
XTANT MEDICAL HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited, in thousands, except number of shares and per share amounts)
| Three Months Ended March 31, | ||||||||
| 2024 | 2023 | |||||||
Revenue | $ | 27,873 | $ | 17,943 | ||||
Cost of sales | 10,571 | 7,407 | ||||||
Gross Profit | 17,302 | 10,536 | ||||||
Gross Profit % | 62.1 | % | 58.7 | % | ||||
Operating Expenses | ||||||||
General and administrative | 7,785 | 4,884 | ||||||
Sales and marketing | 12,460 | 7,054 | ||||||
Research and development | 527 | 174 | ||||||
Total Operating Expenses | 20,772 | 12,112 | ||||||
Loss from Operations | (3,470 | ) | (1,576 | ) | ||||
Other Expense | ||||||||
Interest expense | (835 | ) | (575 | ) | ||||
Interest income | - | 86 | ||||||
Unrealized foreign currency translation loss | (39 | ) | - | |||||
Other income | 12 | - | ||||||
Total Other Expense | (862 | ) | (489 | ) | ||||
Net Loss from Operations Before Provision for Income Taxes | (4,332 | ) | (2,065 | ) | ||||
Provision for Income Taxes | ||||||||
Current and Deferred | (68 | ) | (13 | ) | ||||
Net Loss | $ | (4,400 | ) | $ | (2,078 | ) | ||
Net Loss Per Share: | ||||||||
Basic | $ | (0.03 | ) | $ | (0.02 | ) | ||
Dilutive | $ | (0.03 | ) | $ | (0.02 | ) | ||
Shares used in the computation: | ||||||||
Basic | 130,201,251 | 108,893,588 | ||||||
Dilutive | 130,201,251 | 108,893,588 | ||||||
XTANT MEDICAL HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited, in thousands)
| Three Months Ended March 31, | ||||||||
| 2024 | 2023 | |||||||
Operating activities: | ||||||||
Net loss | $ | (4,400 | ) | $ | (2,078 | ) | ||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
Depreciation and amortization | 1,005 | 471 | ||||||
Gain on sale of fixed assets | (82 | ) | (11 | ) | ||||
Non-cash interest | 95 | 61 | ||||||
Stock-based compensation | 910 | 617 | ||||||
Provision for reserve on accounts receivable | 88 | 106 | ||||||
Provision for excess and obsolete inventory | 259 | 90 | ||||||
Other | 3 | 2 | ||||||
Changes in operating assets and liabilities, net of the effects of the acquisition: | ||||||||
Accounts receivable | (879 | ) | (1,155 | ) | ||||
Inventories | (2,195 | ) | (309 | ) | ||||
Prepaid and other assets | (376 | ) | (68 | ) | ||||
Accounts payable | 492 | (69 | ) | |||||
Accrued liabilities | (675 | ) | 98 | |||||
Net cash used in operating activities | (5,755 | ) | (2,245 | ) | ||||
Investing activities: | ||||||||
Purchases of property and equipment | (773 | ) | (456 | ) | ||||
Proceeds from sale of fixed assets | 99 | 35 | ||||||
Acquisition of Surgalign SPV, Inc. | - | (17,000 | ) | |||||
Net cash used in investing activities | (674 | ) | (17,421 | ) | ||||
Financing activities: | ||||||||
Payments on financing leases | (16 | ) | (15 | ) | ||||
Borrowings on line of credit | 30,445 | 16,495 | ||||||
Repayments on line of credit | (24,797 | ) | (16,871 | ) | ||||
Proceeds from issuance of long term debt | - | 5,000 | ||||||
Debt issuance costs | (436 | ) | (40 | ) | ||||
Payment of taxes from withholding of common stock on vesting of restricted stock units | (17 | ) | - | |||||
Net cash provided by financing activities | 5,179 | 4,569 | ||||||
Effect of exchange rate changes on cash and cash equivalents and restricted cash | (49 | ) | - | |||||
Net change in cash and cash equivalents and restricted cash | (1,299 | ) | (15,097 | ) | ||||
Cash and cash equivalents at beginning of period | 5,923 | 20,507 | ||||||
Cash and cash equivalents at end of period | $ | 4,624 | $ | 5,410 | ||||
Reconciliation of cash and cash equivalents and restricted cash reported in the consolidated balance sheets | ||||||||
Cash and cash equivalents | 4,547 | 5,176 | ||||||
Restricted cash | 77 | 234 | ||||||
Total cash and restricted cash reported in the consolidated balance sheets | $ | 4,624 | $ | 5,410 | ||||
XTANT MEDICAL HOLDINGS, INC.
CALCULATION OF NON-GAAP CONSOLIDATED EBITDA AND ADJUSTED EBITDA
(Unaudited, in thousands)
| Three Months Ended March 31, | ||||||||
| 2024 | 2023 | |||||||
Net Loss | $ | (4,400 | ) | $ | (2,078 | ) | ||
Depreciation and amortization | 1,005 | 471 | ||||||
Interest expense | 835 | 489 | ||||||
Tax expense | 68 | 13 | ||||||
Non-GAAP EBITDA | (2,492 | ) | (1,105 | ) | ||||
Non-GAAP EBITDA/Total revenue | -8.9 | % | -6.2 | % | ||||
NON-GAAP ADJUSTED EBITDA CALCULATION | ||||||||
Non-cash compensation | 910 | 617 | ||||||
Acquisition related expenses | 338 | 211 | ||||||
Acquisition-related fair value adjustments | 1,301 | - | ||||||
Unrealized foreign currency translation loss | 39 | - | ||||||
Non-GAAP Adjusted EBITDA | $ | 96 | $ | (277 | ) | |||
Non-GAAP Adjusted EBITDA/Total revenue | 0.3 | % | -1.5 | % | ||||
SOURCE: Xtant Medical Holdings, Inc.
View the original press release on accesswire.com
FAQ
What was Xtant Medical's revenue growth for Q1 2024?
What is Xtant Medical's revenue guidance for full year 2024?
What was Xtant Medical's net loss for Q1 2024?
How did Xtant Medical's gross margin change in Q1 2024?
What new products did Xtant Medical launch in Q1 2024?
